For over 10 years, one of the cornerstones of the Medicare Part D program has been to ensure the sickest and most vulnerable patients have access to the clinically critical medicines they rely on. For the patients whose treatment is covered under six specific classes of medicines – those with HIV, cancer and epilepsy among others – more commonly known as the six protected classes, there is no “one size fits all” for medicines that will work. The medicines for these patients have complex interactions, side effects, contraindications and other factors that must be considered in their coverage.
Unfortunately, a recently proposed rule from the Centers of Medicare and Medicaid Services (CMS) – the Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses – would be detrimental to Part D beneficiaries and in particular, patients suffering from HIV/AIDS.
The protected classes policy is particularly vital to beneficiaries living with HIV/AIDS, given the public health implications of HIV-positive patients not receiving timely and appropriate treatment. The protected class policy enables HIV patients to access “all or substantially all” HIV medicines, which is crucial given that some strains of the virus may be resistant to certain anti-viral medicines. Additionally, newer single tablet combination regimes are easier for patients to take, leading to improved adherence. If patients do not have access to the full breadth and range of anti-viral treatments, it could be harder to reach the goals of more people with HIV achieving viral suppression.
The proposed rule would weaken the six protected classes by allowing Part D plans to restrict access to medicines by using step therapy or utilization management – a practice that aims to reduce drug costs by requiring patients to initiate on less expensive therapies before the can access more expensive specialty ones. That includes patients who are stable taking HIV medicines. These proposed changes would severely undermine patient access to drugs they need to survive and would be the wrong prescription for Medicare and HIV patients who rely on it.
Precision Health Economics is out with an eye-opening new memo where they note the provision of the proposed rule requiring utilization management could lead to “over 6,750 new HIV infections from increased viral loads among Medicare patients with HIV. Those 6,750 additional infections would be transmitted from the Medicare population but the new cases would be distributed across the general population.”
And, in a recently published op-ed in STAT, author W. David Hardy makes it clear: “Successfully treating HIV, and the even greater goal of ending the HIV pandemic, are based on a fundamental science-backed premise: that all people living with HIV should have early and uninterrupted access to effective antiretroviral medications that suppress the virus and keep it at undetectable levels for the rest of their lives.”
The AIDS Institute also joined the chorus of calls for the Trump administration to reject their “dangerous” Part D rule, stating that “Step therapy and prior authorization should never be used in the treatment of HIV and run counter to the US government sponsored HIV treatment guidelines.”
Patients living with HIV deserve unrestricted access to specific prevention and treatment regimens which are critical to their health and the goal of ending the HIV epidemic. The Medicare Part D protected classes policy has been instrumental in the incredible strides and progress that have been made for HIV treatment in the past decade. As we all work towards the goal of ending the HIV epidemic, reversing this progress is the wrong prescription for Medicare and HIV patients.
Tom Wilbur
Tom Wilbur is Deputy Vice President of Public Affairs at PhRMA where he leads the state public affairs team and Voters for Cures, PhRMA’s grassroots advocacy initiative. Prior to joining PhRMA in 2019, Tom served as a senior aide on Capitol Hill for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom holds an M.A. in strategic communications from Michigan State University and a B.A. in social science and history from Central Michigan University. He enjoys spending time with family and friends, volunteering, reading and golfing.
Medicare Part D at 20: Building on a strong foundation
The IRA’s price setting doesn’t guarantee lower costs or better access
What seniors can expect this open enrollment
Part D premiums are going up, while choices are going down
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
PBMs launch new ad campaign to block reforms
Patients are losing as government price setting continues
CMS needs to do better
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
New survey: Insurers confirm IRA will reduce patient treatment options
The unintended consequences of government price setting in Medicare Part D
What is the low-income subsidy program and how is it changing?
Three things to know about the United Nations’ new HIV/AIDS report
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
IRA is already negatively impacting access to medicines in Part D
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
Watch: Putting patients front and center for World AIDS Day
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
IRA threatens seniors’ access to robust treatment options
Medicare Prescription Payment Plan will benefit patients if implemented correctly
Correcting the record: IRA’s government price setting provisions are unconstitutional
IRA changes to Part D risk access to medicines
With the first list of medicines out, let’s not forget why government price setting is bad policy
One year later IRAs unintended consequences are becoming reality
Four things for CMS to keep in mind as they implement changes to Part D
CMS guidance on IRA price setting process doubles down on bad policy
Medicare Part D open enrollment and what recent changes mean for beneficiaries
Many seniors are paying more for Part D medicines than their insurer
A key fact the White House is reluctant to admit
A key fact the White House is reluctant to admit
Making coupons count for patients with HIV
The Senate’s latest price setting proposal will undermine: Patient access to medicines
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
Post-approval research save lives. Why is Congress trying disincentivize it?
A price control by any other name would still put patients at risk and threaten innovation
New data show insurers and PBMs increase barriers to care
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
Making medicines more affordable: Modernizing Medicare
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
Recent polling misrepresents public support for Medicare “negotiation”
What they’re saying: Patient advocates want to protect Medicare from government interference
Myth vs. fact: Polling and Medicare “negotiation”
ICYMI: Event spotlights how we can make Medicare work better for patients
The future of the rebate rule: Will policymakers stand with patients?
Celebrating Medicare’s 56th anniversary
Government “negotiation” could have devastating consequences for Medicare enrollees
Protecting Medicare from government interference
Data shows voters strongly support protecting access to their medicines
Medicare “negotiation” proposals threaten Americans’ access to medicines
Out-of-pocket trends in Medicare Part D show rising costs for seniors
The ABCs (and Ds) of Medicare
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
Key excerpts: PhRMA submits comments to keep the six protected classes protected
Action needed to preserve the six protected classes
Key facts: The final rebate rule will be a positive change for patients
End of year Part D reading List
Final rebate rule represents right way to change Medicare
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Open Enrollment: How to find a Medicare plan that meets your needs
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Three reasons why repealing the Part D non-interference clause is a bad idea
National Medicare Education Week: The history of Medicare Part D
How Medicare Part D supports patients
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
Supporting access to vaccines for Part D beneficiaries
Medicare’s 55th anniversary: Celebrating the success of Part D
Three reasons why MedPAC’s latest Part D proposal would be bad for patients
PhRMA submits comments on CMS’s Part D specialty tier proposal
Three reasons the Administration should abandon its International Pricing Index proposal
Four reasons why the radical Pelosi Plan is the wrong approach
Three reasons the Senate Finance package is the wrong approach for patients
New analysis: Government intervention in Part B threatens patient access to medicines
Three things to know about the Part D GAO report
No matter how you structure it, government arbitration is wrong for Medicare drug coverage
What you should know: Government arbitration is the wrong way to change Medicare
By the numbers: A look at the Part B International Pricing Index Model
How the rebate rule would help reduce patients’ out-of-pocket costs
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
4 Things to know about the IQVIA “Medicine Use and Spending” report
Event tomorrow: Improving access and affordability for America’s seniors
Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices
Six policy solutions to help patients afford their insulin
PhRMA comments on OIG proposed rule to reform the rebate system
Fact Check: How the Part B International Pricing Index model threatens patient access
OIG proposed rule could help strengthen the Part D market
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy
OptumRX: Sharing rebates with patients is “worth it”
New “Prescription for Medicare” campaign focuses on impacts of wrong and right solutions for Medicare
Repealing Part D noninterference clause threatens access and choice for America’s seniors
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
PhRMA comments to administration on Medicare Part D proposed rule
New research shows changes to the six protected classes would harm most vulnerable patients and are unnecessary
Keep the Six Protected Classes, protected
World AIDS Day 2018: Hope for the future
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
Medicare Part D cliff ahead
Part D cliff looms for seniors, as program stability could be in jeopardy
Diversity of thought fuels next generation of breakthroughs
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
PhRMA urges CMS to share the savings with seniors
Medicare Monday: Helping beneficiaries access vaccines
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
Medicare Monday: Same bad ideas continue to threaten Part D and beneficiary access to medicines
Medicare Monday: Open enrollment is here again
Medicare Monday: Medicare Part D by the numbers
Medicare Monday: What is the Extra Help program?
Medicare Monday: Strengthening access to vaccines for seniors
Medicare Monday: Medicare turns 52!
Medicare Monday: What you need to know about the latest Medicare Trustees report
Medicare Monday: Study finds mortality rates for elderly have decreased every year since creation of Part D
Medicare Monday: It is Medicare’s birthday month!
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Medicare Monday: 3 reasons why repealing Part D’s noninterference clause is a bad idea
Medicare Monday: How government price setting in Part D could reduce innovation, shorten life expectancy for beneficiaries
Medicare Monday: Positive impact of Part D on America’s seniors
ICYMI: New study shows medicines advance life expectancy for HIV patients
Medicare Monday: Why imposing Medicaid-style rebates in Part D is a bad idea
Medicare Monday: Another example of the competitive market at work in Part D
Medicare Monday: A discussion on affordability and access to medicines
Medicare Monday: New study further confirms increased use of generics after Part D
Biopharmaceutical industry’s success reducing disparities for African Americans
Medicare Monday: Did you know … ?
Medicare Monday: How Part D helps patients with heart disease live longer, healthier lives
Medicare Monday: How Medicare helps beneficiaries access needed medicines
Medicare Monday: A refresh on private negotiation in Part D
Medicare Monday: Kicking off 2017 with Medicare resources
Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients
HIVAIDS
Part D
Prescription for Medicare
Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients
Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients